News for United Therapeutics Corporation (UTHR)

After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon.

Market Analysis by covering: Assurant Inc, Huazhu Group Ltd, United Therapeutics Corporation. Read 's Market Analysis on Investing.com

Market Analysis by covering: Assurant Inc, Huazhu Group Ltd, United Therapeutics Corporation. Read 's Market Analysis on Investing.com

United Therapeutics shows strong revenue growth, driven by Tyvaso, and maintains high margins and low debt burden. Read why I rate UTHR stock a Buy.

Besides Wall Street's top -and-bottom-line estimates for United Therapeutics (UTHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

**media[548530]**

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, wi

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks.

United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the other...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Offic

United Therapeutics director Mesa Nilda sells $90,720 in stock

United Therapeutics president Michael Benkowitz sells $3.57 million in stock

OS Therapies Announces Closing of $6 Million Private Placement

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against...